Skip to main content
Article thumbnail
Location of Repository

Protocol for stage 2 of the GaP study (genetic testing acceptability for Paget's disease of the bone) : a questionnaire study to investigate whether relatives of people with Paget's disease would accept genetic testing and preventative treatment if they were available

By Anne L. Langston, Marie Johnston, Clare Robertson, Theresa Marteau, John Weinman, Marilyn McCallum, Zosia Miedzybrodzka, Keith Charnock, Stuart H. Ralston, Jillian Joy Francis, Marion Kay Campbell, Vikki Entwistle and Graeme Stewart MacLennan


Background: Paget's disease of bone (PDB) disrupts normal bone architecture and causes pain, deformity, deafness, osteoarthritis, and fractures. Genetic factors play a role in PDB and genetic tests are now conducted for research purposes. It is thus timely to investigate the potential for a clinical programme of genetic testing and preventative treatment for people who have a family history of PDB. This study examines the beliefs of relatives of people with PDB. It focuses particularly on illness and treatment representations as predictors of the acceptability and uptake of potential clinical programmes. Illness representations are examined using Leventhal's Common Sense Self-Regulation Model while cognitions about treatment behaviours (acceptance of testing and treatment uptake) are conceptualised within the Theory of Planned Behaviour. Methods/Design: A postal questionnaire of non-affected relatives of people with Paget's disease. The sample will include relatives of Paget's patients with a family history of Paget's disease and relatives of Paget's patients without a family history of Paget's disease. The questionnaire will explore whether a range of factors relate to acceptability of a programme of genetic testing and preventive treatment in relatives of Paget's disease sufferers. The questionnaire will include several measures: illness representations (as measured by the Brief Illness Perceptions Questionnaire); treatment representations (as measured by Theory of Planned Behaviour-based question items, informed by a prior interview elicitation study); descriptive and demographic details; and questions exploring family environment and beliefs of other important people. Data will also be collected from family members who have been diagnosed with Paget's disease to describe the disease presentation and its distribution within a family. Discussion: The answers to these measures will inform the feasibility of a programme of genetic testing and preventive treatment for individuals who are at a high risk of developing Paget's disease because they carry an appropriate genetic mutation. They will also contribute to theoretical and empirical approaches to predicting diagnostic and treatment behaviours from the combined theoretical models.We wish to acknowledge the Medical Research Council for financial support of this study. [...] The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health Directorates.Publisher PD

Topics: Attitude to Health, Genetic Screening, Osteitis Deformans, Questionnaires, RA Public aspects of medicine
Publisher: BioMed Central
Year: 2008
DOI identifier: 10.1186/1472-6963-8-116
OAI identifier:

Suggested articles


  1. (2006). A single dose of Zoledronic acid 5 mg achieves more sustained biochemical remission verses daily 30 mg Risedronate in patients with Paget's disease. Calcif Tissue Int
  2. (2005). AL: A causal modelling approach to the development of theory-based behaviour change programmes for trial evaluation. Health Educ Res
  3. (1998). Applying Leventhal's self regulation model to adaptation and intervention in rheumatic disease.
  4. (1967). Attitude & the predicition of behaviour.
  5. (1987). Bijvoet OL: Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
  6. (2002). Buick D: The Revised Illness Perception Questionnaire (IPQ-R). Psychology and Health
  7. (2001). Consequences of disease: testing the WHO International Classification of Impairments, Disabilities and Handicaps (ICIDH) model. Soc Sci Med
  8. (1998). Croyle RT: Psychological responses to genetic testing. BMJ
  9. (2002). Domainspecific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet
  10. (2001). Efficacy of the Theory of Planned Behaviour: A meta-analytic review.
  11. (2005). et al.: Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
  12. (1996). Fidell L: Using Multivariate Statistics
  13. (1995). Frequency and characteristics of familial aggregation of Paget's disease of bone.
  14. (1999). Goals of treatment for Paget's disease of bone.
  15. Health Behavior. In Health Psychology Volume 8. Edited by:
  16. (1984). Illness representations and coping with health threats.
  17. (1997). Implementation intentions & the theory of planned behaviours.
  18. (2002). Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res
  19. (1991). JL: Familial aggregation of Paget's disease of bone.
  20. (1972). Kalton G: Survey methods in social investigation 2nd edition.
  21. (1996). KW: Paget's disease of bone and quality of life.
  22. (2003). Leach RJ: Three novel mutations in SQSTM1 identified in familial Paget's disease of bone.
  23. (2006). Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif Tissue Int
  24. National Assocation of the Relief of Paget's Disease [http://] Pre-publication history The pre-publication history for this paper can be accessed here: pub
  25. (2004). Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res
  26. (1993). One to be taken as directed: Reflections on nonadherence (non-compliance).
  27. (2005). Paget's disease of bone.
  28. (2004). Papapoulos SE: Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum
  29. (1999). PJ: A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
  30. (1993). Reluctance to undergo predictive testing: the case of Huntington disease.
  31. (2000). SH: Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone
  32. (2005). SH: Genetics of Paget's disease of bone. Clin Sci (Lond)
  33. (2002). SH: The pro and con of measles virus in Paget's disease: con.
  34. (2005). SH: Ubiquitinassociated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent.
  35. (2006). The Brief llness Perception Questionnaire.
  36. (1996). The illness perception questionnaire: a new method for assessing the cognitive representation of illness. Psychology and Health
  37. (1991). The theory of planned behaviour. Organizational behavior and Human Decision Processes
  38. Two alternative models of health behaviour and recovery from activity limitations due to acute injury: A prospective study. Psychology and Health
  39. (2004). Two novel mutations at
  40. (2002). V: Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
  41. (2006). What do osteoarthritis health outcome instruments measure? Impairment, activity limitation or participation restriction?

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.